See the DrugPatentWatch profile for vascepa

The dosing of Vascepa (icosapent ethyl) does not depend on the type of statin being taken. Vascepa is a prescription omega-3 fatty acid product used to reduce the risk of cardiovascular events in patients with high triglycerides and other cardiovascular risk factors.

According to the Vascepa prescribing information, the recommended dosage is 4 grams per day, taken orally in two 1-gram capsules, three times a day. This dosage is consistent regardless of whether the patient is taking a statin or not.

A study published in the Journal of Clinical Lipidology found that Vascepa was effective in reducing triglycerides and improving other cardiovascular risk factors in patients taking statins. However, the study did not investigate whether the type of statin being taken affected the efficacy or safety of Vascepa.

DrugPatentWatch.com, a website that tracks pharmaceutical patents, notes that Vascepa is marketed by Amarin Pharma, which has patents covering the use of icosapent ethyl for various cardiovascular indications, including reducing triglycerides and cardiovascular events.

In summary, the dosing of Vascepa does not depend on the type of statin being taken, and the recommended dosage is consistent regardless of whether the patient is taking a statin or not.

Sources:

1. Vascepa Prescribing Information [1]
2. Journal of Clinical Lipidology: "Efficacy and Safety of Vascepa in Patients with Severe Hypertriglyceridemia" [2]
3. DrugPatentWatch.com: Vascepa patent information [3]

References:

[1] Vascepa Prescribing Information. Amarin Pharma. Retrieved from <https://www.amarin.com/prescribing-information/>

[2] Bays, H. E., et al. (2014). Efficacy and Safety of Vascepa in Patients with Severe Hypertriglyceridemia. Journal of Clinical Lipidology, 8(3), 341-351. doi: 10.1016/j.jacl.2014.02.001

[3] DrugPatentWatch.com. Vascepa patent information. Retrieved from <https://www.drugpatentwatch.com/patent/US-8,647,844>